Inhibitor Therapeutics, Inc.
CBTE
Other OTC0.39
USD
-0.09
- -
Inhibitor Therapeutics, Inc.
CBTE
(Other OTC)
Recent
price
0.39
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Inhibitor Therapeutics, Inc. is a clinical-stage pharmaceutical development company specializing in the discovery, development, and commercialization of innovative therapies focused primarily on cancerous and non-cancerous proliferation disorders. The company’s core product portfolio centers on SUBA-Itraconazole, a patented oral formulation of itraconazole, which is being developed for treatment indications including prostate cancer, lung cancer, and Basal Cell Carcinoma Nevus Syndrome. Inhibitor Therapeutics leverages repurposed, already approved active pharmaceutical ingredients (APIs) with significant proprietary intellectual property around itraconazole's oncology applications. The company operates primarily in the United States and is headquartered in Tampa, Florida, having been founded in 1992. Recently, Inhibitor Therapeutics has expanded its scientific advisory board to enhance its clinical development strategies. The company has entered into an exclusive worldwide licensing agreement with Johns Hopkins University to utilize their U.S. patents related to itraconazole and its applications. This strategic alliance aims to strengthen its intellectual property position and accelerate the clinical advancement of its therapeutic candidates. No major acquisitions or funding rounds outside these collaborations have been reported in the last one to two years. The company continues focusing on pioneering oral treatments leveraging its patented drug formulations to improve patient outcomes in oncology.